Maraviroc Patent Expiration

Maraviroc is Used for treating patients infected with CCR5-tropic HIV-1. It was first introduced by Viiv Healthcare Co in its drug Selzentry on Aug 6, 2007. 3 different companies have introduced drugs containing Maraviroc.


Maraviroc Patents

Given below is the list of patents protecting Maraviroc, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Selzentry US7368460

(Pediatric)

Tropane derivatives useful in therapy May 25, 2023

(Expired)

Viiv Hlthcare
Selzentry US7368460 Tropane derivatives useful in therapy Nov 25, 2022

(Expired)

Viiv Hlthcare
Selzentry US6667314

(Pediatric)

Tropane derivatives useful in therapy Feb 06, 2022

(Expired)

Viiv Hlthcare
Selzentry US7576097

(Pediatric)

Tropane derivatives useful in therapy Nov 25, 2021

(Expired)

Viiv Hlthcare
Selzentry US6667314 Tropane derivatives useful in therapy Aug 06, 2021

(Expired)

Viiv Hlthcare
Selzentry US6667314 Tropane derivatives useful in therapy Aug 06, 2021

(Expired)

Viiv Hlthcare
Selzentry US7576097 Tropane derivatives useful in therapy May 25, 2021

(Expired)

Viiv Hlthcare
Selzentry US7576097 Tropane derivatives useful in therapy May 25, 2021

(Expired)

Viiv Hlthcare
Selzentry US6586430 CCR5 modulators Dec 01, 2019

(Expired)

Viiv Hlthcare
Selzentry US6586430 CCR5 modulators Dec 01, 2019

(Expired)

Viiv Hlthcare



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Maraviroc's patents.

Given below is the list recent legal activities going on the following patents of Maraviroc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 28 Sep, 2020 US7576097
Payment of Maintenance Fee, 12th Year, Large Entity 22 Oct, 2019 US7368460
Patent Term Extension Application under 35 USC 156 Filed 16 Jun, 2010 US6667314
Notice of Final Determination -Eligible 23 Feb, 2010 US6667314
FDA Final Eligibility Letter 30 Sep, 2009 US6667314
Patent Issue Date Used in PTA Calculation 18 Aug, 2009 US7576097
Recordation of Patent Grant Mailed 18 Aug, 2009 US7576097
Email Notification 30 Jul, 2009 US7576097
Issue Notification Mailed 29 Jul, 2009 US7576097
Application Is Considered Ready for Issue 16 Jul, 2009 US7576097


Maraviroc's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Maraviroc Generic API Manufacturers

Several generic applications have been filed for Maraviroc. The first generic version for Maraviroc was by Hetero Labs Ltd Unit Iii and was approved on Feb 7, 2022. And the latest generic version is by I 3 Pharmaceuticals Llc and was approved on Aug 17, 2023.

Given below is the list of companies who have filed for Maraviroc generic, along with the locations of their manufacturing plants worldwide.


1. HETERO LABS LTD III

Hetero Labs Ltd Unit Iii has filed for 2 different strengths of generic version for Maraviroc. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.

Strength Dosage Form Availability Application Pathway TE code Launch Date
150MG

tablet Prescription ORAL AB Feb 7, 2022
300MG

tablet Prescription ORAL AB Feb 7, 2022





2. I 3 PHARMS

I 3 Pharmaceuticals Llc has filed for 2 different strengths of generic version for Maraviroc. Given below are the details of the strengths of this generic introduced by I 3 Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
150MG

tablet Prescription ORAL AB Aug 17, 2023
300MG

tablet Prescription ORAL AB Aug 17, 2023